Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Izon Science receives $10.5M investment from Bolton Equities: Christchurch-headquartered nanotech company secures investment to accelerate global growth; appoints top board chairman and directors

Abstract:
Izon Science, the world leading manufacturer of nano-biological separation and characterisation tools, today announced a $10.5M equity investment to support its ambitious global growth plans from Bolton Equities, a New Zealand based private equity investor founded by New Zealand businessman and entrepreneur Murray Bolton.

Izon Science receives $10.5M investment from Bolton Equities: Christchurch-headquartered nanotech company secures investment to accelerate global growth; appoints top board chairman and directors

Christchurch, NZ | Posted on July 28th, 2020

Izon serves blue chip research customers in over 50 countries including all of the top 10 medical research companies, 9 of the top 10 pharmaceutical companies and 49 of the top 50 US universities. A particular area of interest is in extra-cellular vesicles, including exosomes, with the expectation that these will become powerful biomarkers and significantly improve healthcare globally.



Hans van der Voorn, CEO of Izon Science, says: “We are very pleased to welcome Bolton Equities as a shareholder to help Izon execute on its vision to grow into a truly global business. The investment will allow us to accelerate the development of several new technologies that will further help scientists working at the nano-scale to solve important research questions.”

Chris Dineen, CEO of Bolton Equities, says: “Izon captured our interest as it’s developing technology that science really needs. We were impressed with its product suite’s capabilities, recent growth rates, and the management team’s approach to developing the technology in a very pragmatic way. We also saw that we could bring significant value to the business alongside our capital, leveraging Bolton Equities’ strengths in finance, tech and healthcare across key markets.”



Izon’s nano-biological technology and tools include its qEV SEC columns which have rapidly become the extra-cellular vesicles (EV) separation method favoured by experts, and its TRPS measurement system which is the only accurate, standardisable and practical method of measuring complex nano-bio particles, particularly EVs and nanomedicine products.

Izon’s board has been bolstered to coincide with the investment. Tony Barclay, former Fisher & Paykel Healthcare (FPH) CFO and Company Secretary, has been appointed independent chairman and Professor Merryn Tawhai, FRSNZ, the Deputy Director of the Auckland Bioengineering Institute (ABI) and Director of the Medical Technologies Centre of Research Excellence (MedTech CORE), has been appointed as an independent director. Chris Dineen has also been appointed to the board with Guy Bolton, Bolton Equities’ Director and President North America, an experienced pharmaceutical and health tech executive based in the US.



Van der Voorn says, “We’re delighted to have attracted Tony as our new chairman as his extensive background is highly relevant to Izon. Merryn, Chris and Guy also add significant expertise that will be invaluable as we work to make a global impact.”



Barclay says, “Hans and the Izon team have really impressed me - they are taking on the world and winning from New Zealand in a fast growing global niche for nanotech identification and separation technology. I recognise similar characteristics in the company to Fisher & Paykel Healthcare; the company is developing impressive technology that is helping move science forward globally to improve lives. The opportunity is open-ended as the company has the potential to become integral to global diagnosis and therapeutics markets.”



Barclay adds that there are bigger players in the wider market addressing these areas in different ways, but Izon’s technology is gaining a reputation as the leader in the field. “A nice element to the business is the multiple streams of revenue it has created due to its expanding range of nanotech instruments and consumables.”

Dineen adds, “Izon is well-positioned to continue its growth despite COVID-19. The company has demonstrated its ability to respond to disruption and is seeing ongoing demand for their technology from its research customers.”

Much of the demand for Izon’s technology in recent years has been driven by the burgeoning interest in extra-cellular vesicles, including exosomes, and their role in a range of health conditions and major diseases such as dementia and cancer.



Van der Voorn says, “We’re enabling fundamental new science as Izon’s tools and technology allow researchers to simultaneously measure particle size and concentration, with sub-nm precision. We’re opening up new nano-biological research areas that haven’t been previously possible at the same scale and accuracy.


“We’re really excited to see our technology being used for research into exosomes, extracellular vesicles and RNA, as researchers work to identify biomarkers which hold the key to early disease intervention. Biomarkers are a measurable indicator of a biological state and play an important role in risk prediction, screening and diagnosis. Identifying biomarkers associated with a type of cancer, would allow medical researchers to see if a cancer treatment was effective or not, by giving faster feedback on pharmacologic responses to a therapeutic intervention.”


Izon has also seen increasing interest in the application of its technology in virology as researchers around the world seek to better understand COVID-19 and other viruses by using information on virus characterisation and concentrations derived from using Izon’s nano-tech tools. Heightened interest in virology and diagnostics and therapeutic drug development will benefit the company longer-term says van der Voorn.

Future plans may also include an NZX listing adds van der Voorn. “We had started preparing for a possible listing prior to this investment, and that is still an option, but it would now be a few years down the track.”

####

About Izon Science
Izon Science is the world leading manufacturer of nano-biological separation and characterisation tools. Its qEV SEC columns have rapidly become the EV separation method favoured by experts. Izon’s TRPS measurement system is the only accurate, standardisable and practical method of measuring complex nano-bio particles, particularly EVs and nanomedicine products.

About Bolton Equities

www.boltonequities.co.nz

For more information, please click here

Contacts:
Sandra Lukey, Shine Group (PR for Izon)
Phone: +64 21 2262 858

Copyright © Izon Science

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

When Dirac meets frustrated magnetism August 3rd, 2020

New printing process advances 3D capabilities: Technology aims to improve quality of products used in business, industry and at home July 31st, 2020

TU Graz researchers synthesize nanoparticles tailored for special applications July 31st, 2020

Scientists discover new class of semiconducting entropy-stabilized materials July 31st, 2020

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

180 Degree Capital Corp. Reports 15.9% Annual Increase and 0.3% Quarter Increase in Net Asset Value Per Share to $3.06 as of December 31, 2019 February 24th, 2020

180 Degree Capital Corp. to Report Fourth Quarter 2019 Financial Results on Monday, February 24, 2020 and to Host a Conference Call on Tuesday, February 25, 2020 February 20th, 2020

Possible Futures

Physicists find misaligned carbon sheets yield unparalleled properties July 31st, 2020

Way, shape and form: Synthesis conditions define the nanostructure of manganese dioxide July 31st, 2020

New printing process advances 3D capabilities: Technology aims to improve quality of products used in business, industry and at home July 31st, 2020

Scientists discover new class of semiconducting entropy-stabilized materials July 31st, 2020

Investments/IPO's/Splits

180 Degree Capital Corp. Reports Q1 2020 Results and Developments From Q2 2020 May 6th, 2020

180 Degree Capital Corp. Selected to Manage $25 Million by Pension Fund May 6th, 2020

180 Degree Capital Corp. Life Science Portfolio Company Enters Into Definitive Agreement to be Acquired May 6th, 2020

Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences May 1st, 2020

Nanomedicine

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis July 28th, 2020

Silver-plated gold nanostars detect early cancer biomarkers: New optical sensing platform can detect genomic cancer biomarkers directly in patient tissues July 24th, 2020

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care July 21st, 2020

Charcoal a weapon to fight superoxide-induced disease, injury: Nanomaterials soak up radicals, could aid treatment of COVID-19 July 2nd, 2020

Announcements

When Dirac meets frustrated magnetism August 3rd, 2020

New printing process advances 3D capabilities: Technology aims to improve quality of products used in business, industry and at home July 31st, 2020

TU Graz researchers synthesize nanoparticles tailored for special applications July 31st, 2020

Scientists discover new class of semiconducting entropy-stabilized materials July 31st, 2020

Tools

Bruker Launches Revolutionary High-Speed AFM System for Single-Molecule Applications: JPK NanoRacer® Follows Molecular Dynamics in Real Time at 50 Frames per Second July 30th, 2020

Study: Mapping crystal shapes could fast-track 2D materials: Experts call for global effort to clear hurdles to mass production July 27th, 2020

Project creates more powerful, versatile ultrafast laser pulse: Institute of Optics research sets record for shortest laser pulse for newly developed technology, work that has important applications in engineering and biomedicine July 24th, 2020

Scientists open new window into the nanoworld July 17th, 2020

Nanobiotechnology

Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis July 28th, 2020

Silver-plated gold nanostars detect early cancer biomarkers: New optical sensing platform can detect genomic cancer biomarkers directly in patient tissues July 24th, 2020

HORIBA Medical and CEA-Leti Strengthen Their Partnership to Develop Tomorrow’s Diagnostics at the Point of Care July 21st, 2020

Charcoal a weapon to fight superoxide-induced disease, injury: Nanomaterials soak up radicals, could aid treatment of COVID-19 July 2nd, 2020

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project